Hypertrophic scar contraction (HSc) is caused by granulation tissue contraction propagated by myofibroblast and fibroblast migration and contractility. Identifying the stimulants that promote migration and contractility is key to mitigating HSc. Angiotensin II (AngII) promotes migration and contractility of heart, liver, and lung fibroblasts; thus, we investigated the mechanisms of AngII in HSc. Human scar and unwounded dermis were immunostained for AngII receptors angiotensin type 1 receptor (AT1 receptor) and angiotensin type 2 receptor (AT2 receptor) and analyzed for AT1 receptor expression using Western blot. In vitro assays of fibroblast contraction and migration under AngII stimulation were conducted with AT1 receptor, AT2 receptor, p38, Jun N-terminal kinase (JNK), MEK, and activin receptor-like kinase 5 (ALK5) antagonism. Excisional wounds were created on AT1 receptor KO and wild-type (WT) mice treated with AngII±losartan and ALK5 and JNK inhibitors SB-431542 and SP-600125, respectively. Granulation tissue contraction was quantified, and wounds were analyzed by immunohistochemistry. AT1 receptor expression was increased in scar, but not unwounded tissue. AngII induced fibroblast contraction and migration through AT1 receptor. Cell migration was inhibited by ALK5 and JNK, but not p38 or MEK blockade.
Abstract
Hypertrophic scar contraction (HSc) is caused by granulation tissue contraction propagated by myofibroblast and fibroblast migration and contractility. Identifying the stimulants that promote migration and contractility is key to mitigating HSc. Angiotensin II (AngII) promotes migration and contractility of heart, liver, and lung fibroblasts; thus, we investigated the mechanisms of AngII in HSc. Human scar and unwounded dermis were immunostained for AngII receptors angiotensin type 1 receptor (AT1 receptor) and angiotensin type 2 receptor (AT2 receptor) and analyzed for AT1 receptor expression using Western blot. In vitro assays of fibroblast contraction and migration under AngII stimulation were conducted with AT1 receptor, AT2 receptor, p38, Jun N-terminal kinase (JNK), MEK, and activin receptor-like kinase 5 (ALK5) antagonism. Excisional wounds were created on AT1 receptor KO and wild-type (WT) mice treated with AngII±losartan and ALK5 and JNK inhibitors SB-431542 and SP-600125, respectively. Granulation tissue contraction was quantified, and wounds were analyzed by immunohistochemistry. AT1 receptor expression was increased in scar, but not unwounded tissue. AngII induced fibroblast contraction and migration through AT1 receptor. Cell migration was inhibited by ALK5 and JNK, but not p38 or MEK blockade. In vivo experiments determined that absence of AT1 receptor and chemical AT1 receptor antagonism diminished granulation tissue contraction while AngII stimulated wound contraction. AngII granulation tissue contraction was diminished by ALK5 inhibition, but not JNK. AngII promotes granulation tissue contraction through AT1 receptor and downstream canonical transforming growth factor (TGF)-β signaling pathway, ALK5. Further understanding the pathogenesis of HSc as an integrated signaling mechanism could improve our approach to establishing effective therapeutic interventions. 
Introduction
Disability due to hypertrophic scar contraction (HSc) following burn wounds results in approximately $80.2 billion in lost wages worldwide annually [1] . The additional impact of medical expenses, social costs, and emotional trauma due to disfigurement is immeasurable. HSc leads to contractures which are inelastic, thickened scars that fail to regress [2, 3] . These fixed lesions cause pain, deformity, profound itching, and severe disability of joints [3] [4] [5] . Contractures as little as a 10 % reduction in joint motion is clinically significant [6] . Current anti-HSc therapies are ineffective [7] . Thus, there remains an urgent need to understand the pathogenesis of HSc and identify targets to prevent this disabling process. Over the last half century, it has been established that HSc is mediated by myofibroblast and fibroblast contractility and migration. While contractility and migration are known to be caused by intracellular focal adhesion complex formation, cytoskeletal protein activation, and upregulation included but not limited to α-smooth muscle actin (ASMA) [8] , vimentin [7] , non-muscle myosin (NM IIA) [9] , and the regulatory proteins RhoA and Rho kinase (ROCK) [9] , it is unknown which extracellular soluble substances activate these pathways. Angiotensin II (AngII) is one soluble mediator that has been implicated in stimulating pro-fibrotic processes in the heart, liver, kidney, and lung [10] [11] [12] [13] . There is also accumulating evidence that AngII is a key effector in promoting dermal wound healing and fibrosis [14] [15] [16] [17] .
AngII signals through two receptors: angiotensin type 1 receptor (AT1 receptor) and angiotensin type 2 receptor (AT2 receptor). It has been hypothesized that the balance between AT1 receptor vs. AT2 receptor activation determines healing versus fibrosis, but this hypothesis has not been conclusively tested [18, 19] . AngII has been linked to upregulation of transforming growth factor (TGF)-β production and activation of the TGF-β signaling pathways: canonical and noncanonical. In the canonical pathway, TGF-β binds to receptor activin receptor-like kinase 5 (ALK5) which activates the phosphorylation of Smad2/3. Activated Smad2/3 proteins recruit Smad4 and cause nuclear translocation of the Smad2/ 4 or Smad3/4 for activation of pro-contractile messenger RNA (mRNA) transcription [20] . The TGF-β non-canonical signaling pathway involves activation of mitogen-activated protein kinase (MAPK) pathways including, extracellular signalregulated kinase (ERK), Jun N-terminal kinase (JNK), and p38 [21] .
Here, we investigate the AngII signaling mechanism involved in dermal HSc using a combination of experiments on human tissue, human and murine cell lines, and murine granulation tissue contraction models.
Materials and methods

Animals
All protocols were approved by Duke University Medical Center Institutional Animal Care and Use Committee. Two strains of 10-12-week-old mice weighing 18-20 g were used:
(1) C57BL/6J from Jackson Laboratory and (2) AT1 knockout (KO) mice from Thomas Coffman, MD, Duke.
Dermal excisional wounding C57BL/6J mice were randomly divided into control (n=12), losartan (Sigma-Aldrich, St. Louis, MI)-treated group (n=12) fed 50 mg/kg/day losartan by 0.4 ml saline gavage and AngII (Calbiochem, San Diego, CA)-treated group (n=36) implanted with subdermal osmotic pumps (ALZET, Cupertino, CA) to administer 2,200 ng/kg/min AngII dissolved in phosphate-buffered saline (PBS). AngII group had three subgroups (n=8) each administered either ALK inhibitor on day 3 (10 mg/kg of 5 mg/0.25 ml SB431542 (Tocris Bioscience, Bristol, UK) in DMSO by intraperitoneal (IP) injection), JNK inhibitor for 14 days (16 mg/kg/day of SP600125 (SigmaAldrich) in 45 %w/v 2-hydroxypropyl-B cyclodextrin IP), or equivalent amounts of PBS. All mice, including AT1 KO (n= 5), were halothane-anaesthetized and 8-mm full-thickness excisional wounds created on the dorsum. The wound area was measured using gravitational planimetry and expressed as a percentage of original wound size. On days 3, 7, and 14, animals (n=5 per time point per group) were euthanized, and the wound bed was excised with a 5-mm margin of unwounded skin for histological and immunohistochemical (IHC) staining.
Histology
To determine epidermal thickness, collagen deposition, and mast cell infiltration, histological analysis was performed on excised samples by staining with hematoxylin and eosin, Masson's trichrome, and toluidine blue, respectively.
Immunohistochemistry
Samples of human studies were obtained after receiving patient consent and approval of the Xiangya Hospital Ethics Committee. Human hypertrophic scars (HSs) between 10 months and 1 year in maturity were sampled from 12 patients (4 female, 8 male) aged 1 to 45 years old, who had sustained thermal injury (scald, burn) to areas of joint mobility (finger, neck, knee, eyelid). HS and adjacent unwounded skin were retrieved as described by Morihara et al. [14] . Samples underwent IHC detection of AT1 receptor and AT2 receptor by polyclonal rabbit anti-human (N-10, sc-1173 and H-143, sc-9046, Santa Cruz Biotechnology, Dallas, TX). Mouse specimen underwent detection of Ki67 (rabbit anti-mouse, 1:400 dilution, Thermo scientific, Fremont, CA) and F4/80 for macrophages (rat anti-mouse, 1:1500 dilution, eBioscience, San Diego, CA). AT1 receptor, AT2 receptor, and Ki67 binding were recognized with goat anti-rabbit (1:200 dilution, Vector Laboratories, Burlingame, CA). F4/80 binding was recognized with rabbit antirat (1:200 dilution, Vector). Tissue staining was visualized using the avidin-biotinylated enzyme complex system (Vectastain Elite ABC, Vector) and 3,3′-diaminobenzidine substrate chromogen solution (Dako, Carpinteria, CA). Labeled cells were visualized with a Nikon eclipse E600 microscope, and images were captured with a Nikon DXM 1200 digital camera under the same settings. Positively stained cells were counted in 5 high-power fields (HPF) using ImageJ (NIH, Bethesda, MD).
Cell culture
Human cell cultures were exempt by Duke University Medical Center Institutional Review Board (DUMC IRB). HS and adjacent unwounded tissue were excised from the following patients: (1) 21-year-old female, 6-month-old shoulder scar; (2) 42-year-old female, 1.5-year-old chest scar; (3) 39-year-old female, 3-monthold neck scar; and (4) 58-year-old female, 2-month-old breast scar. Human scar fibroblast (HSF) and fibroblasts from unwounded tissue samples were explanted from samples as described by Liu et al. Eight human fibroblast cell lines were established as described by Bond et al. [22] . Western blot, fibroblast-populated collagen lattice (FPLC), and cell migration experiments were conducted with these primary cell cultures when cells became 80-90 % confluent between passages 2-6.
Stress fiber staining
Formation of filamentous actin (F-actin) in 3T3 fibroblasts was analyzed. Cells treated with AngII (0.01, 0.1, 1, and 10 μM) and 5 ng/ml TGF-β (Invitrogen, Carlsbad, CA) were fixed in 4 % paraformaldehyde/1 % gluteraldehyde/PBS, permeabalized in 0.2 % Triton X-100/PBS, blocked with sodium borohydride (0.5 mg/ml) in PBS, and stained with fluorescein phalloidin (0.1 μg/ml, Invitrogen) in PBS.
Cell migration assays
Chemokinetic migration of fibroblasts was assayed by using modified Boyden chamber and cell scratch assays. Boyden chamber assay was performed as described by Bond et al. [22] using 3T3 treated with 0.01 μM AngII or 5 ng/ml TGF-β, and cell scratch was performed using HSF treated in 1 μM AngII or 20 ng/ml TGF-β, as these substrate concentrations were found to elicit the most significant response for the respective cell types and experimental conditions. To conduct the cell scratch assay, HSFs were plated onto 24-well chambers, three chambers per treatment group. At 80-90 % confluence, a scratch was made with a plastic P20 pipet tip, and chambers were rinsed and incubated with inhibitors (ALK5-20 μΜ SB431542, MEK-10 μM U0126 (Cell Signaling, Danvers, MA), p38-10 μM SB203580 (Cell Signaling), JNK-10 μM SP600125), 10 μM losartan, or DMSO control in Dulbecco's modified Eagle's medium (DMEM) for 1 h prior to TGF-β or AngII treatment. Images were taken of scratch area at 0, 24, and 48 h using ×4 air objective, measured using ImageJ freehand measure tool, and area of scratch closure was calculated as a fraction of initial size.
Fibroblast-populated collagen lattice
A mixture of 1.0×10 5 fibroblasts/ml, 1.28 mg/ml purified collagen, (Nutragen, Advanced Biomatrix, Fremont, CA, USA), and 1 % FBS in DMEM (growth media) was added in 400 μl volumes to a 24-well chamber and incubated for 60 min to allow the collagen to polymerize before adding 500 μl of 0.01 μM AngII alone, or AngII and losartan or AngII and PD123319 (Sigma-Aldrich). Lattices were incubated for 24 h, sizes were recorded using a digital scanner 5 h after release, and areas were measured using ImageJ.
Reverse transcription polymerase chain reaction
For 48 h, 3T3 fibroblasts were grown in 0.1 μM AngII. Rho, ROCK, and NM IIA mRNA levels were analyzed by semiquantitative reverse transcription (RT)-PCR using Qiagen RNeasy Universal Plus Mini Kit (Valencia, CA) and Stratagene Mx3005P qPCR system (Santa Clara, CA) as per manufacturer's protocol. Results were analyzed using MxPro QPCR software (Agilent Technologies Inc., Santa Clara, CA). Relative gene expression was calculated as a ratio to housekeeping gene, S9.
Western blot analysis HSF and fibroblasts from unwounded human tissue were used to determine AT1 receptor and AT2 receptor expression. Primary antibodies used were rabbit anti-AT1 receptor (1 μg/ml Santa Cruz Biotechnology) and rabbit anti-AT2 receptor (1 μg/ml LifeSpan BioSciences, Inc., Seattle, WA). Incubated in 0.1 μM AngII for 4 days prior to experiment, 3T3 fibroblasts were used to determine NM IIA, vimentin, ASMA, and ROCK expression. Primary antibodies used were rabbit anti-NM IIA (1:1000 dilution Abcam, Cambridge, MA), goat antivimentin (1:200 dilution, eBioscience), rabbit anti-ASMA (1:200 dilution Abcam), and rabbit anti-ROCK (1:200 dilution, Abcam). WB analysis was performed as described by Bond et al. [22] .
Statistics
The statistical analysis was performed with IBM Statistical Package for the Social Sciences Statistics 17 software program. All quantitative data are presented as the mean and standard error of the mean (SEM) of three independent experiments, performed in triplicate for each condition, using each of the three mice. Statistical analysis was performed by using either analysis of variance (ANOVA) or two-sided Student's t test where appropriate. Difference was considered significant at p≤0.05. 
Results
Angiotensin type 1 receptor expression is increased in scar tissue compared to unwounded tissue; angiotensin type 2 receptor is not
We investigated the involvement of AT1 receptor and AT2 receptor in HSc using IHC analyses of receptor expression in human HS and surrounding unwounded skin. In unwounded skin, both receptors were expressed in eccrine sweat glands (Fig. 1b) , myoepithelial cells (Fig. 1c) , arrector pili muscle (Fig. 1d) , and vascular endothelial cells (Fig. 1e ), but absent in dermal fibroblasts (Fig. 1f) . However, in HS, while both AT1 receptor and AT2 receptor were expressed in vascular endothelial cells (Fig. 1h) , only AT1 receptor was expressed in HSF (Fig. 1i) . Western blot quantification demonstrated significantly increased expression of AT1 receptor in HSF compared to unwounded fibroblasts (p<0.05, Fig. 1j, k) . Western blotting of AT2 receptor in HSF did not identify any receptor expression (not shown). To determine the effects of AngII on the cytoskeleton, fibroblasts were stimulated with AngII and stained for F-actin expression with FITC-labeled phalloidin (Fig. 2a-e) . Compared to control, F-actin expression was significantly increased in AngII-treated cells and in a dose-dependent manner (Fig. 2a-c) . Cells treated with 0.1 μM AngII sparsely expressed F-actin (Fig. 2b) , whereas cells treated with 1 μM AngII had condensed F-actin throughout the cytoplasm (Fig. 2c) . As expected, the effects of AngII were abrogated by the AT1 receptor inhibitor, losartan (Fig. 2e) . AngII also increased the mRNA expression of the pro-contractile and migration mediators RhoA, ROCK, and NM IIA (Fig. 2f) . While TGF-β treatment also induced expression of RhoA, ROCK, and NM IIA, in the case of ROCK, AngII was more effective. Similarly, at the protein level, AngII increased the expression of ROCK, NM IIA, vimentin, and ASMA (Fig. 2g, h ). These findings support a role for AngII in stimulating expression of cytoskeletal proteins responsible for migratory and contractile properties in fibroblasts. Fig. 3 Angiotensin II induces fibroblast migration and contraction through AT1 receptor. Boyden chamber assay demonstrating increased migration in 3T3 fibroblasts incubated in DMEM with 0.01 μM AngII for 4 days prior to experiment relative to control (a). AT1 receptor inhibition with losartan decreases AngII-stimulated migration whereas AT2 receptor inhibition with PD123319 does not. Untreated control group was incubated in DMEM alone; TGF-β (5 ng/ml) is positive control. Data are mean±SEM, n=6. *p<0.05;^p>0.05. HSF-populated collagen lattices (FPCL) incubated for 4 days with 0.01 μM AngII in 1 % FBS demonstrate significantly decreased lattice size compared to untreated control group (1 % FBS alone) 5 h after lattice release (b). AngII-treated normal fibroblast collagen lattices demonstrate no significant change in lattice size compared to the untreated group. Data are mean±SEM, n=9. ANOVA scar fibroblast *p<0.05, normal fibroblasts^p>0.05. Two-way ANOVA, p<0.05. AT1 receptor inhibition with losartan decreases 0.01 μM AngII-stimulated contraction (c) whereas AT2 receptor inhibition with PD123319 does not. Data are mean±SEM, n=6. *p<0.05; p>0.05
Angiotensin II stimulates fibroblast migration and contraction through angiotensin type 1 receptor
We investigated the AT1 receptor-specific effects of AngII on cellular migration and contractility. AngIIstimulated fibroblasts had significantly increased migration relative to untreated cells (Fig. 3a) . Inhibition of AT1 receptor with losartan significantly decreased AngII-induced migration. In contrast, inhibition of AT2 receptor with PD123319 did not alter AngII-induced migration. We found similar results regarding fibroblast contraction wherein AngII-induced FPCL contraction was increased in scar fibroblasts (Fig. 3b) , an effect that was significantly diminished by AT1 receptor blockade (Fig. 3c) , but not AT2 receptor blockade. Taken together, these results suggest that AngII stimulates scar fibroblast migration and contraction through AT1 receptor.
Angiotensin II stimulates fibroblast migration through activin receptor-like kinase 5-and Jun N-terminal kinase-mediated signaling To gain insight into how AngII stimulates fibroblast migration, we investigated the role of the canonical and noncanonical TGF-β signaling pathways using small molecule inhibitors. At 48 h after AngII or TGF-β stimulation, ALK5 or JNK inhibition resulted in a statistically significant decrease in migration by 24 % (*p<0.02) and 14 % (*p<0.007), respectively (Fig. 4a, b) . p38 or MEK inhibition yielded 23 % (p<0.2) and 14 % (p<0.42) decrease in migration, but these were not statistically significant effects (Fig. 4c, d ). These results suggest that the TGF-β receptor, ALK5, and TGF-β non-canonical signaling mediator, JNK, are involved in AngII-induced cellular migration.
Angiotensin II stimulates wound contraction through angiotensin type 1 receptor using an activin receptor-like kinase 5-mediated mechanism
We studied the role of AngII, ALK5, and JNK signaling in granulation tissue contraction using dermal excisional wounds in C57BL/6J wild-type (WT) and AT1 KO mice treated with AngII±losartan, ALK5, or JNK inhibition. Granulation tissue contraction was significantly delayed in the KO mice compared to WT mice on days 3, 4, and 5 ( Fig. 5a) , demonstrating the importance of AT1 receptor in tissue contraction. At each time point, contraction rates in AngII-treated WT mice were significantly increased compared to control (Fig. 5b) .
Conversely, losartan significantly delayed contraction compared to control (Fig. 5c, d) . As of day 9 after injury, contraction rates in AngII/SB431542-, but not SP600125, treated mice were significantly diminished (Fig. 6a, b) . At day 14, average wound size decrease in AngII/SB431542-treated groups was 52 %, but greater and comparable in AngII alone and AngII/ SP600125-treated groups with respective 73 and 71 % decrease. These data demonstrate that AngII-stimulated granulation tissue contraction is mediated by an AT1 receptor signaling pathway to which ALK5 is an integral component.
Angiotensin type 1 receptor, activin receptor-like kinase 5, and Jun N-terminal kinase blockade do not significantly alter re-epithelialization, collagen deposition, and cell proliferation
We assessed the effects of AT1 receptor, ALK5, and JNK blockade on wound epithelial regeneration, collagen formation, and cell proliferation by performing H&E, Masson's trichrome, and Ki67 staining on tissue samples from respective treatment groups. No significant difference was observed on the gross histological analysis of epithelial regeneration, collagen deposition, or epidermal and dermal cell proliferation between losartan-treated and control groups (Fig. 7a) . With respect to ALK5 and JNK inhibition, there was no statistical difference between these groups in re-epithelialization, collagen deposition, or cell proliferation (Fig. 8a-d) .
Angiotensin type 1 receptor and activin receptor-like kinase 5 blockade diminish mast cell and macrophage infiltration, respectively Inflammation is a well-characterized modulator of wound healing. To determine the effects of AT1 receptor, ALK5, and JNK blockade on macrophage and mast cell infiltration, we immunostained wound samples with F4/80 antibody and toluidine blue. In both losartan-treated and control groups on day 3, there was marked infiltration of F4/80-positive macrophages in the dermis, particularly the superficial dermis, with only a few localized to the connective tissue (Fig. 9a) . However, no significant difference in the number of macrophages per HPF was noted between losartan-treated and control groups at any time point (Fig. 9b) . There was no significant difference between the control and losartantreated groups on days 3 and 7, but on day 14, the control group had significantly higher number of mast cells than the losartan-treated group (21±2 vs. 10±2, Fig. 9d ). ALK5-inhibited samples exhibited significantly lower macrophage recruitment compared to the other groups (Fig. 10a) . Neither ALK5 nor JNK inhibition conferred significant differences in mast cell infiltration compared to control (Fig. 10a, b) .
Discussion
Recent studies have shown that AngII plays an important role in dermal scarring [14, 15, 18] . As reported by Morihara et al., there is increased expression of angiotensin-converting enzyme (ACE) by human keloid and HSc fibroblasts as compared to unwounded fibroblasts [14] . AngII has been reported as one of the key molecules upregulated in the matrix of deep fibroblasts from stiffened, pathologic scar [16] . Of the two widely studied AngII receptors, AT1 receptor is characterized as the primary regulator for AngII-mediated dermal fibrosis. In one study on the effects of thermal skin injury on the renin-angiotensin system in a murine model, the data indicated that AT1 receptor expression was increased in the fibroblasts of injured mice but absent in the fibroblasts of unwounded skin [23] . Similarly, AT1 receptor, as compared to AT2 receptor, was found to be more prominently expressed in the dermis of wounded rats [24] . In HSF, AngII has been shown to stimulate pro-fibrotic pathway, PI3K/Akt, in an AT1 receptor-, but not in an AT2 receptor, dependent manner [18] . One mechanism by which AngII accelerates wound closure may be through AT1 receptor-mediated activation of proteins that promote cellular contraction and migration [25] . Previously published studies have suggested that AngII stimulates components of the cytoskeleton, including RhoA, ROCK, ASMA, and NM IIA [22, 26] . RhoA is the small GTPase activator of actinstabilizing kinase, ROCK1, which is the calcium-independent activator of myosin regulatory light chain [26] . Myosin regulatory light chain stimulates NM IIA activity and promotes actin filament sliding, including ASMA [27] . Normal dermal wound healing includes the processes of (1) re-epithelialization, (2) connective tissue matrix deposition, and (3) contraction, which are dependent on keratinocyte migration and proliferation, collagen deposition, and cellular contraction along the extracellular matrix, respectively [28, 29] . Losartan did not alter re-epithelialization, collagen architecture, or cell proliferation in granulation tissue in the first 14 days. Therefore, losartan most likely inhibited wound healing by diminishing fibroblast contraction and migration. Decreased mast cell recruitment in the losartan group is another possible explanation for delayed wound contraction observed here. Increased numbers of mast cells are present in cutaneous and systemic fibrotic conditions [30] . Mast cell degranulation releases growth factors and cytokines in the wound bed that stimulate cell proliferation, angiogenesis, and extracellular matrix formation that facilitates wound contraction and closure [30, 31] . One study reported that chymase, a protease released from mast cells, may be responsible for ACE-independent generation of AngII in wounds [31] . This may explain why inhibition of mast cell degranulation significantly decreases AngII in thermally injured hamster wounds [31] . Based on these data, there appears to be a positive feedback loop between AngII, AT1 receptor, and mast cells.
In our investigation of HSF migration using cell scratch assay, ALK5 and JNK inhibitor treatment groups had decreased AngII-stimulated HSF migration. However, in vivo findings revealed that only ALK5 inhibition significantly diminished contraction. This could be explained by the fact that AngII upregulates TGF-β, and thus, ALK5 signaling is an important component of AngII effects in promoting contraction [32] . AngII and TGF-β form a concerted signaling network in propagating fibrosis. AngII upregulates TGF-β expression, and in turn, TGF-β increases AT1 receptor expression. This is supported by other studies demonstrating that inhibition of ALK5 significantly diminishes fibrotic changes in hepatic and pulmonary models of fibrosis [33, 34] .
The applicability of these conclusions is limited by the experimental models used in the study. To determine effects of AngII on the cytoskeleton, 3T3 cells were used, whereas human tissue was used for the AngII receptor staining, and human fibroblasts were used in the functional assays. For in vivo experiments, mice were studied for the effects of AngII on granulation tissue contraction rate and immunohistochemistry. Alternative HSc models could further validate the results. In a model of HSc using a rabbit ear model, Uzun et al. found that animals treated with the ACE inhibitor, enalapril, had decreased fibroblast density, capillary density, and scar elevation, as compared to groups treated with intralesion steroids-the current standard of care treatment for HSc [15] . The authors hypothesized that the mechanism through which enalapril diminished hypertrophic scarring was prevention of AngII-AT1 receptor stimulation of TGF-β. This is similar to our findings which implicate AngII as a proscarring soluble factor that activates AT1 receptor and promotes granulation tissue contraction by potentiating the canonical signaling mechanisms of TGF-β.
Dermal scar contracture is a large unmet clinical need. Presently, no effective therapies exist [35] . An effective therapy would mitigate the overexuberant wound healing response that leads to HSC but also allow adequate extracellular matrix deposition and granulation tissue to prevent the opposite problem of non-healing. As such, an anti-HSc agent would be detrimental to a non-healing wound (not fully epithelialized) but beneficial to a HSc (epithelialized wound that is contracting). Our findings demonstrated that AngII accelerates HSF migration in vitro and wound contraction in vivo and that these effects were prevented by AT1 receptor and ALK5 blockade. Thus, our data suggests that AT1 receptor or ALK5 blockade would be beneficial in mitigating HSc. Of course, this would mean that an AT1 receptor or ALK5 antagonist should be applied after the wound has healed and before the hypertrophic scar has developed. Of note, Iannello et al. reported two observational case studies where matured (greater than 4 months old) post-surgical HSc and keloid scars significantly improved after 6 months of treatment with 10 mg of enalapril daily [17] .
In conclusion, we have demonstrated that AngII promotes granulation tissue contraction through AT1 receptordependent cellular migration and contractility. AT1 receptor stimulates the shared ALK5 and JNK non-canonical TGF-β signaling pathway in vitro but only ALK5 is relevant in vivo. 
